India Caps Trade Margins on 137 Anti-Cancer Drugs, Prices Expected to Drop by Up to 70 Percent

India's National Pharmaceutical Pricing Authority has capped trade margins on 137 non-scheduled anti-cancer drugs at 30 percent of MRP, effective November 9. The regulation is expected to reduce prices by up to 70 percent and generate annual savings of approximately ₹2,500 crore, expanding a 2019 initiative that had previously capped margins on 42 cancer drugs.

A 30 percent cap on trade margins across 137 non-scheduled anti-cancer medicines — put in place through an NPPA directive — has drawn analyst projections that retail prices on those drugs could fall by up to 70 percent. A 2019 pilot scheme had already placed upper price limits on 42 oncology medicines, cutting the maximum retail cost of 526 branded products by up to 90 per cent and generating patient savings put at ₹984 crore annually — and the new measures draw on that groundwork to extend the same regulatory reach across a broader range of treatments.

India Caps Trade Margins on 137 Anti-Cancer Drugs, Prices Expected to Drop by Up to 70 Percent

Related Posts

India Caps Trade Margins on 137 Anti-Cancer Drugs, Prices Expected to Drop by Up to 70 Percent

Related Posts